Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Adocia is Extending its Intellectual Property to New Formulations of Monoclonal Antibodies

Published: Tuesday, October 23, 2012
Last Updated: Tuesday, October 23, 2012
Bookmark and Share
These patents cover innovative formulations of monoclonal antibodies enabling a subcutaneous injection, in order to improve patients’ lives and reduce treatment costs.

Adocia has announced that it has filed another three patent applications covering new formulations of monoclonal antibodies.

More specifically, these patent applications relate to original formulations that facilitate the subcutaneous administration of antibodies, as well as innovative formulations that reduce antibody aggregation.

Monoclonal antibodies are therapeutic proteins that are effective in treating numerous chronic diseases: cancer, osteoporosis, multiple sclerosis and other inflammatory diseases. At present, these proteins are mostly administered intravenously.

Subcutaneous administration is now the preferred method as it makes patients’ lives easier and reduces the costs of treatment.

This mode of administration, however, requires a highly-concentrated formulation of monoclonal antibodies. These have a high viscosity and create problems when it comes to administration with subcutaneous injection systems.

Two of the patent applications filed by Adocia relate to innovative formulations that efficiently reduce the viscosity of concentrated antibody solutions.

In a third application, Adocia is seeking patent protection for a new, simple and effective means of reducing antibody aggregation in both concentrated and diluted solutions.

The regulatory authorities in the United States (FDA) and Europe (EMA) are more demanding, since these aggregates can be immunogenic and can result in the treatment being halted.

“We have clearly identified the specific problems that these proteins pose for the pharmaceutical industry,” said Olivier Soula, Adocia’s research director. “We think our innovative formulations provide effective, low-cost solutions to these problems. We are currently presenting the new formulations to a large number of pharmaceutical companies, who are showing considerable interest in them.”

Adocia is already involved in two collaborations with biopharmaceutical companies and intends to enter into more.

“Adocia is continuing to innovate in major pharmaceutical industry applications,” said the company’s president and CEO, Gerard Soula. “The monoclonal antibody market represents a major opportunity for us, since it was worth USD 45 billion in 2011 and is expected to reach USD 58 billion in 2016.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adocia Reports Positive Results from Phase IIa Clinical Study of BioChaperone® Lispro
The ultra-fast action of BioChaperone Lispro should make a positive impact on short and long-term glycemic control, improving the medical benefit for patients.
Friday, April 11, 2014
Adocia Confirms Positive Clinical Results for its BioChaperone® Combo
BioChaperone Combo is the first combination based on insulin glargine to show a fast and long action in type I diabetic patients.
Friday, March 21, 2014
Adocia Strengthens its Diabetic Foot Ulcer Patent Portfolio
The patent on the BioChaperone® polymer used in the PDGF composition recently granted in the United States.
Thursday, January 16, 2014
Adocia Launches Phase IIa Clinical Trial for its Ultra-fast Acting Formulation of Analog Insulin
The aim is to confirm on type I diabetic patients the positive results obtained during phase I.
Tuesday, January 07, 2014
Adocia Signs an Exclusive License on a Nanotechnology
Preclinical results have already demonstrated its remarkable action on solid tumors.
Monday, December 09, 2013
Adocia Announces Initiation of a Clinical Trial on its Combination of Glargine and Lispro
This phase I/II clinical trial on Type I diabetics seeks to compare the performance of this Combo based on insulin Glargine with HumalogMix®.
Monday, November 18, 2013
Adocia Announces Revenues of EUR 4.7 M for the Third Quarter of 2013
The company maintained available cash at EUR 22.7 M.
Thursday, October 24, 2013
Adocia Reacquires Exclusive Development Rights to Ultra-Fast Acting Insulin Analog
Adocia and Lilly terminate collaboration.
Tuesday, July 30, 2013
Adocia Announces its Phase III Development Program for the Treatment of DFU
This program has been validated by scientific advice from the European Medicines Agency.
Wednesday, March 20, 2013
Adocia Announces a Strengthened Intellectual Property on its Lead Project for its Chronic Wounds Treatment
USPTO and EPO have issued a patent to Adocia covering BioChaperone PDGF formulations for chronic wound treatment.
Thursday, June 14, 2012
Adocia Reports Positive Phase II Clinical Results for the Treatment of Diabetic Foot Ulcer
Adocia’s spray formulation of PDGF-BB, combined with BioChaperone®, has been evaluated versus Regranex®, gel of PDGF-BB.
Tuesday, April 24, 2012
Adocia Reports Positive Phase I Clinical Results on HinsBet®, a Fast-Acting Human Insulin
Study on healthy volunteers of a formulation using Adocia’s BioChaperone® platform showed fast onset of action, excellent local tolerance, absence of pain and low inter-patient variability.
Wednesday, March 16, 2011
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!